Change in fatigue 6 weeks after treatment initiation with intravenous iron or intravenous placebo in dependence of the serum ferritin concentration at baseline
| . | Iron group . | Placebo group . | P . |
|---|---|---|---|
| Baseline ferritin ≤ 15 ng/mL (n = 34) | |||
| Change of fatigue (BFI), median | −1.8 (−2.5, −0.8) | −0.4 (−1.2, 0.0) | .005 |
| Fatigue improved (SPI), n (%) | 14/17 (82%) | 8/17 (47%) | .03 |
| Baseline ferritin > 15 ng/mL (n = 56) | |||
| Change of fatigue (BFI), median | −0.7 (−1.8, 0.0) | −0.8 (−1.4, 0.0) | ns |
| Fatigue improved (SPI), n (%) | 14/26 (54%) | 11/30 (37%) | ns |
| . | Iron group . | Placebo group . | P . |
|---|---|---|---|
| Baseline ferritin ≤ 15 ng/mL (n = 34) | |||
| Change of fatigue (BFI), median | −1.8 (−2.5, −0.8) | −0.4 (−1.2, 0.0) | .005 |
| Fatigue improved (SPI), n (%) | 14/17 (82%) | 8/17 (47%) | .03 |
| Baseline ferritin > 15 ng/mL (n = 56) | |||
| Change of fatigue (BFI), median | −0.7 (−1.8, 0.0) | −0.8 (−1.4, 0.0) | ns |
| Fatigue improved (SPI), n (%) | 14/26 (54%) | 11/30 (37%) | ns |
Results are presented as median values (quartiles Q1, Q3) or number of patients (%). P values were calculated with the Mann Whitney U test or the χ2 test.
ns indicates not significant and no trend (P > .10).